GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Replek AD (XMAE:REPL) » Definitions » EV-to-FCF

Replek AD (XMAE:REPL) EV-to-FCF : (As of Apr. 08, 2025)


View and export this data going back to . Start your Free Trial

What is Replek AD EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Replek AD's Enterprise Value is MKD4,360 Mil. Replek AD's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was MKD0 Mil. Therefore, Replek AD's EV-to-FCF for today is .

The historical rank and industry rank for Replek AD's EV-to-FCF or its related term are showing as below:

XMAE:REPL' s EV-to-FCF Range Over the Past 10 Years
Min: -21.98   Med: 0   Max: 0
Current: -21.98

XMAE:REPL's EV-to-FCF is ranked worse than
100% of 547 companies
in the Drug Manufacturers industry
Industry Median: 24.12 vs XMAE:REPL: -21.98

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-08), Replek AD's stock price is MKD15620.00. Replek AD's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was MKD601.447. Therefore, Replek AD's PE Ratio (TTM) for today is 25.97.


Replek AD EV-to-FCF Historical Data

The historical data trend for Replek AD's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Replek AD EV-to-FCF Chart

Replek AD Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.33 48.27 -98.08 10.49 -22.62

Replek AD Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 10.49 - - -22.62

Competitive Comparison of Replek AD's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Replek AD's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Replek AD's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Replek AD's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Replek AD's EV-to-FCF falls into.


;
;

Replek AD EV-to-FCF Calculation

Replek AD's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=4359.996/0
=

Replek AD's current Enterprise Value is MKD4,360 Mil.
Replek AD's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MKD0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Replek AD  (XMAE:REPL) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Replek AD's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=15620.00/601.447
=25.97

Replek AD's share price for today is MKD15620.00.
Replek AD's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MKD601.447.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Replek AD EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Replek AD's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Replek AD Business Description

Traded in Other Exchanges
N/A
Address
Kozle 188, Skopje, MKD
Replek AD is engaged in the development, design and production of generic medicines. The company develops drugs in different pharmaceutical therapeutic categories including anti-platelet, lipid-lowering, atypical antipsychotic, anti-infective, among others. It manufactures drugs in different forms including tablets, capsules, oral solutions, creams and ointments. Its product portfolio consists of Clopidogrel, Atorvastatin, Simvastatin, risperidone, Clarythromycin, Ciprofloxacin, Meloksikam, Risperidon, terazosin, among others. Replek also offers cannabis oil products, food supplements and cosmetics.